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Abstract
Antimicrobial photodynamic therapy (PDT) utilizing porphyrins has emerged as a possible ancillary
treatment against antibiotic resistant bacteria. Porphyrins, such a novel zinc containing porphyrin
designated ZnP, create reactive oxygen species that are toxic to bacterial cells utilizing light by a
mechanism that is not yet fully understood. Previous experiments have shown ZnP to be able to kill
microorganisms in the dark which is unique to few porphyrins. The aim of this research is to understand the
effect ZnP has on Mycobacterium smegmatis, a model organism for the pathogenic bacterium
Mycobacterium tuburculosis which causes the lung infection tuberculosis. Further experimentation is to
include understanding the effects of ZnP on M. smegmatis biofilm formation and disruption as well as
antibiotic uptake in formerly antibiotic resistant cells.
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Introduction
Antibiotic resistance has gained attention within the scientific and healthcare
communities as the problem continues to worsen not just here in the United States but
globally. The miracle of antibiotics has been met by the growing reality that new
technologies must be developed to combat seemingly incurable infections. Drugresistant strains of bacteria do not respond to traditional treatment with antibiotics which
poses a threat to the lives of those infected and all in close proximity to them. There has
been a collective push by researchers and healthcare professionals to begin developing
alternative treatments to what are now being called “superbug” infections in addition to
practicing antibiotic stewardship in clinical settings.
Infections caused by bacteria that are classified by the genus Mycobacterium have
proven to be difficult to treat with loss of limb or life likely in patients without proper
diagnosis and antibiotics. Common illnesses caused by the opportunistic infections from
Mycobacterium species are the respiratory infection, tuberculosis, as well as skin
infections such as leprosy and aquarium granuloma. According to the Centers for
Disease Control and Prevention, the incidence rate of antibiotic resistant strains of the
bacterium that causes tuberculosis has decreased slightly domestically; however, the
number of known cases abroad has more than doubled (CDC, 2015). The necessity to
develop ancillary treatments has become urgent as widespread antibiotic resistant
infections reach epidemic proportions.
A possible treatment is photodynamic therapy which utilizes emerging technology to
treat infections caused by bacteria that are resistant to other methods. In the past
photodynamic therapy has attempted to harness the power of visible light in combination
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with a photosensitizer chemical, to kill malignant and pathogenic cells by damaging their
structure or metabolic pathways. The goal of my project is to gather data to advance the
effectiveness and understanding of porphyrin technology utilizing a patented novel
porphyrin under dark conditions as a possible antibacterial treatment against infections
caused by Mycobacterium species.
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Background and Significance
Antibiotic Resistance in Healthcare Settings
Antibiotic resistance in healthcare settings has the potential to be catastrophic if the
trends that are being seen continue. During one year in the United States the Centers for
Disease Control estimate that there are upwards for 2 million illnesses due to antibiotic
resistance and as many as 23,000 deaths according to the most recent data released in
2015. Since the publication of this data by the CDC, the first pan-drug resistant infection
was seen in a urinary tract infection caused by Escherichia coli in May of 2016 (The
Washington Post, 2016). As the pharmaceuticals that are used as the last-line of defense
begin to fail, common infections can become fatal without the development of alternative
treatments.
A secondary issue that presents as antibiotic resistance continues worsen is the
occurrence of virulent opportunistic pathogens causing harm for patients. Most notably
are infections caused by Pseudomonas auerginosa, methicillin resistant Stahpylococcus
aureus (MRSA), and Clostridium difficle. With symptoms ranging from uncontrollable
diarrhea to tissue necrosis to the point of loss of limb, opportunistic pathogens create
another costly outcome of antibiotic resistance. Disrupting the human microbiome with
broad-spectrum antibiotics creates the perfect environment for bacteria that are present in
normal to undergo a population explosion (e.g. Clostridium difficle infections).
According to the National Institutes of Health the use of broad-spectrum antibiotics
is on the rise since new antibiotics are not being developed (Doron and Davison, 2011).
A microbial imbalance can wreak havoc on a person’s body, called dysbiosis, leading to a
need for antibiotics that work with greater specificity. By initially targeting the
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pathogenic microbe through alternative treatments, broad-spectrum antibiotics can be
used less and lead to more positive outcomes following treatment.
As the list of antibiotic resistant species of microbes continues to grow there is a
call for antibiotic stewardship at both the medical and consumer levels. Overuse and over
prescription of antibiotics is a large proponent to the problem being faced by the medical
community. With the implementation of stricter standards and tighter regulation, the
occurrence of opportunistic pathogen infections will likely decrease as seen in Figure 2
(Talpaert, et al, 2011). Although a large portion of antibiotic use originates out of the
medical community, other areas contribute to resistance such as agriculture and farming
practices as well as the presence of antibiotics in household items such as hand soap. By
increasing the amount of exposure to antibiotics in the daily lives of the average
population there is an increased risk for the development or transfer of resistance genes
which can have devastating impacts in the future. Some may argue that future is nearer
that currently anticipated.

Porphyrin Technology as a Possible Solution
An emerging technology that is being explored as a possible alternative to
antibiotics are treatments utilizing photosensitizers called porphyrins. Porphyrins are
highly conjugated, heterocyclic compounds with a transition metal constituent central to
the structure. Treatment with this type of compound is referred to as antimicrobial
photodynamic therapy or APDT. In this therapy porphyrins (which are light sensitive)
are activated by visible light adjusted to the appropriate wavelength to illicit excitation.
Mechanism is seen in Figure 3. Upon excitation, the photosensitizer catalyzes a reaction
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with the oxygen present in the aerobic environment to create reactive oxygen species
(Banerjee, et al). The porphyrin itself remains unconsumed at the completion of the
reaction. Changing the constituents attached to the ring structure or the transition metal in
the center of the porphyrin have resulted in different APDT properties observed.

Current Clinical Uses of Porphyrin Technology
The current clinical uses of porphyrin technology are limited to infections or rapidly
dividing cell conditions on surfaces that are able to be exposed to light. Trials done in the
field of oncology in recent years have yielded positive results. Photosensitizer technology
is beneficial in these cases by inciting rapid cell lysis in the vasculature supplying
malignant tumors (O’Connor, et al, 2009). Another condition that APDT is proving
useful for is macular degeneration. Research suggests that porphyrin treatment can
restore visual acuity for extended periods of time in individuals with the age-related from
of the condition (TAP Study Group, 2001). Photodynamic therapy has the possibility for
specificity to target diseases involving rapidly dividing cells that lead to serious
conditions.

Patented ZnP Porphyrin
Dr. Jayne B. Robinson Ph.D. of the biology department and Dr. Shawn Swavey
Ph.D. of organic chemistry at the University of Dayton published a patent in February of
2016 for a novel porphyrin meso-5,10,15-tris(N-methyl-4-pyridyl)-20-(pentafluorophenyl) porphyrinatozinc, (II), tris-p-toluene sulfonate, referred to as ZnP. Structure can be
seen in Figure 4. ZnP is a transition metal porphyrin with a zinc ion constituent in the
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center and has a fundamental characteristic specific to this porphyrin – dark toxicity. The
ability for ZnP to be able to kill bacteria in the absence of light increases the potential use
of porphyrin technology to inhibit infections under a wide variety of conditions. Testing
has shown that ZnP is not harmful to adjacent healthy tissues and structures not the target
of treatment making it an appealing alternative treatment for clinical infections. Due to
the stability of the compound and ability to produce therapeutic results without harming
eukaryotic tissues possible routes of administration are orally, intravenously, or by
metered dose inhaler (Robinson and Swavey, 2016).

Dark Therapy Porphyrins and Hypothesized Mechanism
While the light mechanism for porphyrin photodynamic therapy is well-studied,
hypotheses for the dark therapy mechanism are only beginning to be developed. Since
toxicity is unrelated to photon excitation and creation of reactive oxygen species, the
mechanism inhibits bacterial growth by another pathway. One possibility is that ZnP
uptake causes perforations in the cell wall of a bacterial cell leading to the uptake of the
porphyrin and the devastating effects of intracellular structures effluxing out of the cell.
After ZnP is uptaken into the cell a second hypothesis supported by data recently
gathered show evidence that ZnP intercalates with bacterial DNA to inhibit transcription
(Figure 5).
Disruption of cellular function in this way may be dependent upon the
composition of the cell wall which was proven to be null by ZnP having bactericidal
effects again Gram positive and Gram negative bacteria Staphylococcus aureus and
Pseudomonas aeruginosa (Robinson, 2014). Having a cell-wall dependent hypothesis
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creates interest in understanding the mechanism of uptake and bactericidal growth
inhibition in the dark with Mycobacterium smegmatis. Comparison of bacterial cell walls
can be seen in Figure 6.

Mycobacterium smegmatis as a Model Organism
The bacteria Mycobacterium smegmatis serves as a model organism for
Mycobacterium tuberculosis since both of the microorganisms display similar
physiological characteristics and morphology. Cells classified under the genus
Mycobacterium have a characteristic cell wall with a high density of lipids which gives
rise to the microbe’s unique antibiotic resistant qualities (Parish, 2008). The advantage
of working with M. smegmatis is that it is a non-pathogenic strain and is able to be safely
used in laboratory facilities on the University of Dayton’s campus. The decision to use
M. smegmatis as the organism in question was two-fold with the first reason being
porphyrin technology has not been tested on any species of its kind. The second reason is
the domestic and international significance of the devastating effects of Mycobacterium
infections cause and what that means for healthcare providers and patients alike.
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Figure 1
Diagram courtesy of the CDC.
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Figure 2
Data from Talpert, et al, 2011 showing the impact of the introduction of revised broadspectrum antibiotic stewardship data on the occurrence of Clostridium difficile infections.
Significant reduction in infections was seen post introduction of guidelines.
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Figure 3
Diagram of the mechanism of light reactions utilizing porphyrins to create reactive
oxygen species in aerobic environments which are toxic to bacterial species.
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Figure 4
Structure of the novel Zn porphyrin patented by Dr. Jayne B. Robinson Ph.D. and Dr.
Shawn Swavey Ph.D. (2016).
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Figure 5
Visual representation of intercalation courtesy of The Perkins Lab at University of
Colorado, Boulder. There is evidence that ZnP intercalates between base pairs disrupting
bacterial cell transcription.
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Figure 6
The diagram above details the components of different classifications of bacteria based
upon cell wall constituents - Gram positive, Gram negative and Mycobacteria. Cell wall
may play a role in the dark mechanism of ZnP.
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Preliminary Data
One standard, and widely used porphyrin is 5,10,15,20-Tetrakis(4-methoxyphenyl)21H,23H-porphine tetra-p-tosylate salt or TMP, structure can be seen in Figure 7. In past
studies, TMP has shown a high rate of killing planktonic Pseudomonas aeruginosa cells
in the light, however, TMP is unable to produce the same effect on P. aeruginosa cells in
the dark (Robinson, 2014). The results found for TMP are in contrast to a second, novel
patented porphyrin Zn PHPTMP, or ZnP. The advantage of using ZnP in contrast to
TMP, is that in experiments using organisms such as Pseudomonas aeruginosa and
Staphylococcus aureus not only did the porphyrin possess light toxicity but dark toxicity
as well (Robinson, 2016).
Biofilms formed by P. aeruginosa in vitro were treated with TMP in light
conditions and data collected (Figure 8) supported the claim that TMP was able to reach
the bacteria through the biofilm layers (Collins, et al, 2010). A second experiment was
done that tested the toxicity of TMP involving exposing a biofilm of P. aeruginosa to the
porphyrin under dark conditions and then treating the experimental cultures with
antibiotics. Live dead stains differentiate between live cells with intact cytoplasmic
membranes that appear green and cells considered dead with a compromised membrane
that appear red to show the effectiveness of antimicrobial treatments. After completing a
live dead stain, it was revealed that although the biofilm was formed before being
exposed to TMP, the antibiotics were able to reach the bacteria and kill the vast majority
of cells growing as seen in Figure 9.
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Figure 7
Structure of TMP exhibiting the highly conjugated carbon ring structure typical of
porphyrins.
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Light only

225 μM TMP + light

100 μM TMP + light

225 μM TMP (no light)

Figure 8
Live Dead Stain of Pseudomonas aeruginosa from a previous experiment published by
Collins, et al. The cells fluorescing green are live cells, the cells fluorescing red are dead
cells.
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Tobromycin Only

TMP + Antibiotic Tobromycin

Figure 9
Live dead stain of Pseudomonas aeruginosa from a previous experiment published by
Collins, et al (green = live cells, red = dead cells). The porphyrin TMP is shown to
increase the effectiveness and killing capacity of the antibiotic tobramycin.
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Materials and Methods
Culturing Specifics
The cultures of Mycobacterium smegmatis were taken from -60° F freezer stocks and
grown initially on sterile Luria broth (LB) agar plates, a nutrient rich and non-selective
media. Cultures were grown aerobically in a 37° C incubator for three days per the
average growth time and specifics for M. smegmatis (Philly study). Isolate colonies were
selected using a sterile loop and used to inoculate specified liquid media for further
experimentation.

Ananerobic Killing Assays
M. smegmatis colonies were selected from LB agar plates and grown in 10mL liquid
minimal salt glucose media (MSG). Cultures were places on a shaker at 180 RPMs in a
37° C incubator for 3 days. The liquid culture was diluted to an optical density (OD) of
0.15 using sterile 0.1% peptone solution in an autoclaved 150mL flask and placed back
on the shaker in the incubator for a duration of one hour. Using three sterile 1mL
centrifuge tubes, a control and two subsequent concentrations (25mM and 50mM) of ZnP
porphyrin were prepared. The control contained 900 μL of 0.15 OD M. smegmatis culture
suspended in peptone and 100 μL of sterile H 2 O to equal a total volume of 1 mL. The
first experimental trial had a concentration of 25 μM of ZnP. The porphyrin was filter
sterilized and suspended in sterile water. 900 μL of 0.15 M. smegmatis was added to a 1
mL sterile centrifuge tube. To achieve the proper concentration, 50 μL of ZnP porphyrin
stock with a concentration of 0.5mM was added in addition to 50 μL of sterile H 2 O to
achieve a total volume of 1mL. The final experimental trial had a concentration of 50 μM
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of ZnP porphyrin. 900 μL of 0.15 M. smegmatis was added to a 1 mL sterile centrifuge
tube. To achieve the proper concentration, 100 μL of ZnP porphyrin was added to
achieve a total volume of 1mL. A 96 well plate was used to complete seven 10-1 serial
dilutions. The dilutions were then plated in 10 μL aliquots on LB media agar plates at
time points zero, seven and twenty-four hours. The plates were grown aerobically in a
37° C incubator for three days. Between time points the centrifuge tubes were kept in
static conditions in the incubator and plated directly. Qualitative morphology results and
plate count data were gathered after three days of growth. Plate count data was graphed to
track the effect of bacterial growth inhibition due to the porphyrin.

Aerobic Killing Assays
The same protocol was followed as for the anaerobic killing assay however between time
points the centrifuge tubes were aerobically grown on a shaker at 180 RPMs in a 37°C
incubator. The serial dilutions were plated in 10 μL aliquots on LB media agar plates at
time points zero and twenty-four hours. Qualitative morphology results and plate count
data were gathered after three days of growth. Plate count data was graphed to track the
effect of bacterial growth inhibition due to the porphyrin.

Resistant Colony Isolation
The aerobic killing assay experimental trials data revealed a few individual colonies
growing on the 50 μM ZnP porphyrin LB plate for the twenty-four hour time point. The
colonies were selected using a sterile inoculating loop and streaked on Lownstien-Jensen
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selective media that is selective for Mycobacterium species. Qualitative morphology
results were gathered after three days of growth.

Fluorescent Microscopy
Fluorescent microscopy was used to visualize the uptake of ZnP over a set of time point
in a culture of M. smegmatis using an Olympus BX51 fluorescence microscope. The
cultures were grown under conditions identical to the killing assay trials. When the
control, 25 μM and 50 μM centrifuge tubes were properly prepared, 10 μL aliquots of
each were placed on microscope slides and secured with glass cover slips to be viewed.
Images were taken at time point zero, after 45 and 120 minutes. High power objectives
viewed under oil immersion. The fluorescence filter used was Texas Red at an excitation
wavelength of 561 nm and an emission wavelength of 615 nm (Abramowitz and
Davidson, 2012).
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Results
Anaerobic Killing Assay
Plate count data (CFUs/mL) gathered after three days of incubation showed insignificant
reduction over the 24 hour time period. The data can be seen in Figure 10. Standard error
bars can be seen. Qualitative findings revealed a change in the morphology of colony
forming units, however, bactericidal effects were not apparent. When isolate colonies of
the altered morphology were streaked on to new sterile LB agar plates, wild type rescue
was not seen suggesting a true alteration of M. smegmatis morphology and no reversion
back to wild-type growth.

Aerobic Killing Assay
Altering the protocol to keep the bacteria exposed to ZnP growing under aerobic
conditions drastically changed the plate count data gathered. At the 24 hour time point
there was near-complete clearing of both 25mM and 50 mM ZnP concentration trials.
Data is presented in Figure 11. Standard error bars are present. Qualitative findings
revealed the few single colony isolates that appeared on the 50 mM ZnP concentration
LB agar plate to be phenotypically similar with wild-type M. smegmatis.

Resistant Colony Isolation
Single colony isolates from 50 mM ZnP trial were streaked using a sterile inoculating
loop on LJ medium and revealed substantial growth after an incubation at 37° C for a
period of 3 days.
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ZnP Porphyrin Uptake Visualized with Fluorescent Microscopy
Control images taken of MSG liquid media and initial M. smegmatis culture revealed no
significant findings. Time point zero showed faint fluorescence but definition of single
cells present in the visual field. After 45 minutes elapsed individual cells could be more
clearly seen emitting a red fluorescent glow which was retained for all time periods
between 45 minutes and 120 minutes post exposure to ZnP. Images show evidence of
porphyrin uptake rather than simple adherence to the exterior cell wall of individual
bacterium. Images can be seen in Figure 12.
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Aerobic Killing Assay
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Figure 11
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A

B

C

Figure 12
A) M. smegmatis, 45 min post exposure, 25mM ZnP, Texas Red, Fluorescent
Microscope, 100X, Oil immersion B) M. smegmatis, 45 min post exposure, 50mM ZnP,
Texas Red, Fluorescent Microscope, 100X, Oil immersion C) M. smegmatis, 120 min
post exposure, 50mM ZnP, Texas Red, Fluorescent Microscope, 100X, Oil immersion
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Discussion and Future Directions
Porphyrin technology has the potential for being an alternative treatment for
antibiotics as they become ineffective and research starts to move away from developing
new antibiotic pharmaceuticals. ZnP in particular is an important compound due to its
ability to effectively kill a range of bacterial organisms each with distinct characteristics.
The additional benefit of porphyrins being able to increase the therapeutic effect of
current antibiotics provides hope that common infections may not become deadly in
coming years.
The results gathered from exposing Mycobacterium smegmatis to ZnP provides
evidence of the potential clinical use of this compound against lung infections like
tuberculosis. Being able to better define the effects of ZnP in aerobic and anaerobic
conditions advances the understanding of how it would perform in vivo since the lungs
have sites of characterized by different levels of oxygenation. To gather data in vitro that
explores the possibilities of ZnP’s therapeutic effect can lead to more well defined and
efficient procedures in future studies.
The finding that ZnP is successful in killing Mycobacterium smegmatis provides a
foundation for future testing to further quantify the therapeutic effects of porphyrin dark
therapy. Due to the specificity of ZnP the promise of its use in clinical settings on human
patients is almost tangible. Seeing as that is a hope for the far future there is still data that
needs to be gathered to be able to move forward with implementation. A minimal lethal
concentration (MLC) must be defined in order to most effectively use resources when
treating infections caused by M. smegmatis. To better understand the possible impact that
mycolic acid and other constituents of the cell wall of Mycobacterium species, the M.
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smegmatis MLC can be compared to Gram positive and Gram negative MLC data. If
dark therapy porphyrins do in fact have a mechanism dependent upon the bacterial cell
wall then analysis of the data may reveal trends based upon cell wall makeup.
Another area that can be more well defined is not only the rate of ZnP uptake in
wild-type M. smegmatis cells but the uptake of additional substances post-exposure. The
importance of this data would be to see if antibiotics or other pharmaceuticals can be
transferred to the intracellular environment for a therapeutic effect. Mycolic acid is fairly
difficult to penetrate with current therapies which using the theory that ZnP is able to
pass through the cell wall and possibly leave openings to allow exchange. In the event
ZnP does interact with the cell wall this way, porphyrin dark therapy could increase the
effectiveness of additional bactericidal therapies that exist but have low efficacy under
current conditions.
Antibiotic resistance being a pressing issue and horizontal uptake of resistance
genes causing troublesome outlooks for the future of infectious disease, porphyrin dark
therapy may prove useful. Data gathered on the effect of ZnP exposure on antibiotic
resistant strains of bacteria has the possibility increasing the therapeutic effect of current
pharmaceuticals. Increased uptake of additional substances can lead to using technology
already as a more efficient use of resources.
Whether or not the isolate colonies seen on 50mM aerobic killing assay LB agar plates
were truly resistant is another area that will take additional trials. Of the trials, isolate
colonies like these were only seen in one of the replicates per trial. If truly resistant,
frequency of resistance must be determined and further experimentation includes
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exposing subcultures to ZnP at varying concentrations higher than 50mM to see how
often and under what conditions do similar colonies appear.
The final aspect that is to be explored that was beyond the scope of this project is to
determine the effectiveness of either porphyrin (TMP or ZnP) on biofilm formation of the
model organism. Previous experiments have shown the ability of porphyrins to penetrate
the seemingly impenetrable external matrix produced by biofilms. Historically bacterial
biofilms have prevented antibiotics from being effective against established biofilms due
to the secretion of polymeric substances.
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